341 related articles for article (PubMed ID: 32518275)
1. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
Kumar DP; Caffrey R; Marioneaux J; Santhekadur PK; Bhat M; Alonso C; Koduru SV; Philip B; Jain MR; Giri SR; Bedossa P; Sanyal AJ
Sci Rep; 2020 Jun; 10(1):9330. PubMed ID: 32518275
[TBL] [Abstract][Full Text] [Related]
2. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.
Akbari R; Behdarvand T; Afarin R; Yaghooti H; Jalali MT; Mohammadtaghvaei N
BMC Pharmacol Toxicol; 2021 Oct; 22(1):53. PubMed ID: 34593018
[TBL] [Abstract][Full Text] [Related]
3. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.
Jain MR; Giri SR; Bhoi B; Trivedi C; Rath A; Rathod R; Ranvir R; Kadam S; Patel H; Swain P; Roy SS; Das N; Karmakar E; Wahli W; Patel PR
Liver Int; 2018 Jun; 38(6):1084-1094. PubMed ID: 29164820
[TBL] [Abstract][Full Text] [Related]
4. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
Gawrieh S; Noureddin M; Loo N; Mohseni R; Awasty V; Cusi K; Kowdley KV; Lai M; Schiff E; Parmar D; Patel P; Chalasani N
Hepatology; 2021 Oct; 74(4):1809-1824. PubMed ID: 33811367
[TBL] [Abstract][Full Text] [Related]
5. Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids.
Sarkar S; Kumari D; Gupta SK; Sharma V; Mukhi S; Kamboj P; Sasibhushan V; Rai RK; Jatavallabhula SL; Mahajan D; Kumar Y; Kumar A; Dikshit M
Biomed Pharmacother; 2021 Dec; 144():112357. PubMed ID: 34794234
[TBL] [Abstract][Full Text] [Related]
6. Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD.
Ezhilarasan D
Metabolism; 2024 Jun; 155():155912. PubMed ID: 38609038
[TBL] [Abstract][Full Text] [Related]
7. Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis.
Hassan NF; Nada SA; Hassan A; El-Ansary MR; Al-Shorbagy MY; Abdelsalam RM
Inflammation; 2019 Jun; 42(3):1056-1070. PubMed ID: 30737662
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the Potential Role of
Srinivas AN; Suresh D; Suvarna D; Pathak P; Giri S; Suman ; Satish S; Chidambaram SB; Kumar DP
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834657
[TBL] [Abstract][Full Text] [Related]
9. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
[TBL] [Abstract][Full Text] [Related]
11. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
Kaul U; Parmar D; Manjunath K; Shah M; Parmar K; Patil KP; Jaiswal A
Cardiovasc Diabetol; 2019 Jun; 18(1):80. PubMed ID: 31208414
[TBL] [Abstract][Full Text] [Related]
12. Saroglitazar, a novel dual PPAR-α/γ agonist, reverses high fat-low protein diet-induced metabolic and cognitive aberrations in C57BL/6J male mice.
Dharavath RN; Arora S; Kondepudi KK; Bishnoi M; Chopra K
Life Sci; 2021 Apr; 271():119191. PubMed ID: 33571514
[TBL] [Abstract][Full Text] [Related]
13. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
Abd El-Haleim EA; Bahgat AK; Saleh S
Eur J Pharmacol; 2016 Feb; 773():59-70. PubMed ID: 26825546
[TBL] [Abstract][Full Text] [Related]
14. Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis.
Banini BA; Kumar DP; Cazanave S; Seneshaw M; Mirshahi F; Santhekadur PK; Wang L; Guan HP; Oseini AM; Alonso C; Bedossa P; Koduru SV; Min HK; Sanyal AJ
Hepatology; 2021 Apr; 73(4):1290-1306. PubMed ID: 33131062
[TBL] [Abstract][Full Text] [Related]
15. Saroglitazar for the treatment of dyslipidemia in diabetic patients.
Joshi SR
Expert Opin Pharmacother; 2015 Mar; 16(4):597-606. PubMed ID: 25674933
[TBL] [Abstract][Full Text] [Related]
16. RLA8-A New and Highly Effective Quadruple PPAR-
Li MH; Chen W; Wang LL; Sun JL; Zhou L; Shi YC; Wang CH; Zhong BH; Shi WG; Guo ZW
J Pharmacol Exp Ther; 2019 Apr; 369(1):67-77. PubMed ID: 30745416
[TBL] [Abstract][Full Text] [Related]
17. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
18. A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis.
Siddiqui MS; Idowu MO; Parmar D; Borg BB; Denham D; Loo NM; Lazas D; Younes Z; Sanyal AJ
Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2670-2672. PubMed ID: 33152542
[TBL] [Abstract][Full Text] [Related]
19. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.
Siddiqui MS; Parmar D; Sheikh F; Sarin SK; Cisneros L; Gawrieh S; Momin T; Duseja A; Sanyal AJ
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2597-2605.e2. PubMed ID: 36731585
[TBL] [Abstract][Full Text] [Related]
20. The dual PPAR-α/γ agonist saroglitazar ameliorates thioacetamide-induced liver fibrosis in rats through regulating leptin.
Makled MN; Sharawy MH; El-Awady MS
Naunyn Schmiedebergs Arch Pharmacol; 2019 Dec; 392(12):1569-1576. PubMed ID: 31367862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]